- A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer
-
Park J, Eoh KJ, Nam EJ, Kim S, Kim SW, Kim YT, Lee JY
- KMID: 2471913
- Yonsei Med J.
- 2020 Apr;61(4):284-290.
- doi: 10.3349/ymj.2020.61.4.284
PURPOSE: We evaluated whether adding bevacizumab to current platinum-based chemotherapy could improve clinical outcomes without affecting safety. MATERIALS AND METHODS: We retrospectively reviewed medical records of patients with pathologically confirmed ovarian... -
- CITED
-
- Close
- SHARE
-
- Close
- Germline PALB2, ATM variants in a patient with breast and ovarian cancer at risk for familial cancer syndrome: Is there a role for risk-reducing salpingo-oophorectomy?
-
Carbajal-Mamani SL, Markham MJ, Santolaya-Forgas J, Castagno J, Cardenas-Goicoechea J
- KMID: 2471759
- Obstet Gynecol Sci.
- 2020 Mar;63(2):205-208.
- doi: 10.5468/ogs.2020.63.2.205
A 50-year-old non-Hispanic white Caucasian female was diagnosed with breast cancer and was subsequently found to possess the tumorigenic ataxia telangiectasia mutated (ATM) and PALB2 variants but not the BRCA1... -
- CITED
-
- Close
- SHARE
-
- Close
- Robotic-assisted interval cytoreductive surgery in ovarian cancer: a feasibility study
-
Carbajal-Mamani SL, Schweer D, Markham MJ, Esnakula A, Grajo JR, Castagno J, Cardenas-Goicoechea J
- KMID: 2471752
- Obstet Gynecol Sci.
- 2020 Mar;63(2):150-157.
- doi: 10.5468/ogs.2020.63.2.150
OBJECTIVE: The primary objective was to assess the feasibility of robotic-assisted interval cytoreductive surgery for achieving complete cytoreduction for patients with advanced-stage ovarian cancer. The secondary objective was to examine... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison between weekly versus 3-weekly paclitaxel in combination with carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer
-
Kim YN, Lee YJ, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT
- KMID: 2470873
- J Gynecol Oncol.
- 2020 Mar;31(2):e23.
- doi: 10.3802/jgo.2020.31.e23
OBJECTIVE: To compare the efficacy and toxicity of dose-dense weekly paclitaxel and 3-weekly carboplatin (ddPC) as neoadjuvant chemotherapy (NAC) with the standard 3-weekly regimen. METHODS: A retrospective study of patients diagnosed... -
- CITED
-
- Close
- SHARE
-
- Close
- Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study
-
Park SJ, Kim J, Kim HS, Lee JW, Chang HK, Lee KH, Kim DY, Kim S, Chang SJ, Han SS, Park SY, Shim SH
- KMID: 2470868
- J Gynecol Oncol.
- 2020 Mar;31(2):e15.
- doi: 10.3802/jgo.2020.31.e15
OBJECTIVE: To evaluate the effectiveness and safety of the combination of pegylated liposomal doxorubicin with carboplatin (CD) compared with those of carboplatin and paclitaxel (CP) for platinum-sensitive recurrent ovarian, fallopian,... -
- CITED
-
- Close
- SHARE
-
- Close
- Tozzi classification of diaphragmatic surgery in patients with stage IIIC–IV ovarian cancer based on surgical findings and complexity
-
Tozzi R, Ferrari F, Nieuwstad , Campanile , Soleymani Majd H
- KMID: 2470867
- J Gynecol Oncol.
- 2020 Mar;31(2):e14.
- doi: 10.3802/jgo.2020.31.e14
OBJECTIVE: To introduce a systematic classification of diaphragmatic surgery in patients with ovarian cancer based on disease spread and surgical complexity. METHODS: For all consecutive patients who underwent diaphragmatic surgery during... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of neoadjuvant chemotherapy versus primary debulking surgery in patients with ovarian cancer: a meta-analysis
-
Lv X, Cui S, Zhang X, Ren C
- KMID: 2470865
- J Gynecol Oncol.
- 2020 Mar;31(2):e12.
- doi: 10.3802/jgo.2020.31.e12
OBJECTIVE: Neoadjuvant chemotherapy (NACT) for the treatment of epithelial ovarian cancer (EOC) has remained controversial. This meta-analysis was performed to systematically assess the efficacy and safety of NACT versus primary... -
- CITED
-
- Close
- SHARE
-
- Close
- BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies
-
Lee A, Moon BI, Kim TH
- KMID: 2460908
- Ann Lab Med.
- 2020 Mar;40(2):114-121.
- doi: 10.3343/alm.2020.40.2.114
Hereditary breast cancer is known for its strong tendency of inheritance. Most hereditary breast cancers are related to BRCA1/BRCA2 pathogenic variants. The lifelong risk of breast cancer in pathogenic BRCA1... -
- CITED
-
- Close
- SHARE
-
- Close
- How to predict treatment failure in frail patients with advanced epithelial ovarian cancer: strategies to personalize surgical effort
-
Fotopoulou C
- KMID: 2465193
- J Gynecol Oncol.
- 2020 Jan;31(1):e26.
- doi: 10.3802/jgo.2020.31.e26
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery
-
Liu YL, Filippova OT, Zhou Q, Iasonos A, Chi DS, Zivanovic O, Sonoda Y, Gardner GJ, Broach VA, O'Cearbhaill RE, Konner JA, Aghajanian C, Long Roche K, Tew WP
- KMID: 2465191
- J Gynecol Oncol.
- 2020 Jan;31(1):e17.
- doi: 10.3802/jgo.2020.31.e17
OBJECTIVE: Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) confers similar outcomes as primary debulking surgery and chemotherapy. Little is known about patients who receive NACT but do not... -
- CITED
-
- Close
- SHARE
-
- Close
- Factors associated with surgical morbidity of primary debulking in epithelial ovarian cancer
-
Günakan E, Tohma YA, Tunç M, Akıllı H, Şahin H, Ayhan A
- KMID: 2467933
- Obstet Gynecol Sci.
- 2020 Jan;63(1):64-71.
- doi: 10.5468/ogs.2020.63.1.64
OBJECTIVE: Epithelial ovarian cancer (EOC) requires an aggressive surgical approach. The important part of literature on ovarian cancer surgery emphasize residual tumor and survival analyses. Morbidity issue keeps in background.... -
- CITED
-
- Close
- SHARE
-
- Close
- Potential predictors for chemotherapeutic response and prognosis in epithelial ovarian, fallopian tube and primary peritoneal cancer patients treated with platinum-based chemotherapy
-
Jeerakornpassawat D, Suprasert
- KMID: 2467932
- Obstet Gynecol Sci.
- 2020 Jan;63(1):55-63.
- doi: 10.5468/ogs.2020.63.1.55
OBJECTIVE: This study aimed to investigate the potential predictive factors for platinum resistance and poor prognosis in epithelial ovarian, fallopian tube, and primary peritoneal cancer treated with platinum-based chemotherapy. METHODS: Medical... -
- CITED
-
- Close
- SHARE
-
- Close
- Contralateral Breast Cancer and Ipsilateral Breast Tumor Recurrence in BRCA1/2 Carriers and Non-Carriers at High-Risk of Hereditary Breast Cancer
-
Yoon KH, Chae S, Kang E, Shin HC, Kim JH, Kim IA, Park SY, Kim SW, Kim EK
- KMID: 2470895
- J Breast Cancer.
- 2019 Dec;22(4):587-598.
- doi: 10.4048/jbc.2019.22.e47
PURPOSE: We evaluated the risk of contralateral breast cancer (CBC) and ipsilateral breast tumor recurrence (IBTR) and investigated the predictive factors for CBC and IBTR in breast cancer patients with... -
- CITED
-
- Close
- SHARE
-
- Close
- Knowledge and Anxiety Related to Hereditary Ovarian Cancer in Serous Ovarian Cancer Patients
-
Lee SH, Lee H, Lim MC, Kim S
- KMID: 2465979
- Korean J Women Health Nurs.
- 2019 Dec;25(4):365-378.
- doi: 10.4069/kjwhn.2019.25.4.365
PURPOSE: The awareness of hereditary breast and ovarian cancer (HBOC) and BRCA testing is increasing in Korea. Compared to the sizable research on HBOC knowledge among breast cancer women, studies... -
- CITED
-
- Close
- SHARE
-
- Close
- MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B
-
Niu Q, Liu Z, Gao J, Wang Q
- KMID: 2463793
- Yonsei Med J.
- 2019 Dec;60(12):1146-1156.
- doi: 10.3349/ymj.2019.60.12.1146
PURPOSE: Chemoresistance is a concern in ovarian cancer patients, in whom survival remains. MicroRNA, a novel class of small RNAs, have frequently been found to be dysregulated in human malignancies... -
- CITED
-
- Close
- SHARE
-
- Close
- Incidental Ovarian Lesions
-
Kang S, Park JJ, Park SY
- KMID: 2464907
- J Korean Soc Radiol.
- 2019 Nov;80(6):1060-1074.
- doi: 10.3348/jksr.2019.80.6.1060
Incidental ovarian lesions are diagnostic challenges owing to their wide disease spectrum, ranging from normal findings to malignant ovarian tumors. There are several physiologic ovarian lesions that may not require... -
- CITED
-
- Close
- SHARE
-
- Close
- Prevalence and oncologic outcomes of BRCA1/2 mutation and variant of unknown significance in epithelial ovarian carcinoma patients in Korea
-
Seo JH, Jeong SY, Kim MS, Kang JH, Paik ES, Lee YY, Kim TJ, Lee JW, Kim BG, Bae DS, Choi CH
- KMID: 2462119
- Obstet Gynecol Sci.
- 2019 Nov;62(6):411-419.
- doi: 10.5468/ogs.2019.62.6.411
OBJECTIVE: BRCA mutational status is important in the management of ovarian cancer, but there is a lack of evidence supporting genetic testing in Asian populations. This study was performed to... -
- CITED
-
- Close
- SHARE
-
- Close
- Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?
-
Zang R, Zhu J
- KMID: 2458912
- J Gynecol Oncol.
- 2019 Nov;30(6):e116.
- doi: 10.3802/jgo.2019.30.e116
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Neoadjuvant chemotherapy for epithelial ovarian cancer in Japan: a JSGO-JSOG joint study
-
Machida H, Matsuo K, Enomoto T, Mikami M
- KMID: 2458909
- J Gynecol Oncol.
- 2019 Nov;30(6):e113.
- doi: 10.3802/jgo.2019.30.e113
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D
-
Lee JY, Kim JW, Lim MC, Kim S, Kim HS, Choi CH, Yi JY, Park SY, Kim BG, on behalf of KGOG investigators
- KMID: 2458908
- J Gynecol Oncol.
- 2019 Nov;30(6):e112.
- doi: 10.3802/jgo.2019.30.e112
BACKGROUND: A single-arm phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in the treatment of advanced-stage ovarian cancer has begun in Korea. We hypothesized that adding durvalumab (anti-programmed... -
- CITED
-
- Close
- SHARE
-
- Close
